Fukui H, Shibata T, Naito T, Nakano J, Maejima T, Senda H, Iwatani W, Tatsumi Y, Suda M, Arika T
Central Research Institute, Kaken Pharmaceutical Co., Ltd., Kyoto, Japan.
Bioorg Med Chem Lett. 1998 Oct 20;8(20):2833-8. doi: 10.1016/s0960-894x(98)00514-9.
The titled compounds were synthesized and evaluated for in vitro antibacterial activity. The (3R, 4S)-3-aminomethyl-4-trifluoromethyl derivative (S-34109) was confirmed to be optimal because of its superior activity against quinolone and methicillin-resistant Staphylococcus aureus and low side effect potential.